RE:RE:RE:PanCAN 2nd annual Therapeutic Accelerator Award Goes to ONCYpelaboost as per PanCan - The Therapeutic Accelerator Award enables the next phase of research for this exciting work by funding an early-phase clinical trial testing the investigational treatment combination: Oncolytics’ proprietary reovirus pelareorep in combination with modified FOLFIRINOX chemotherapy with or without an immune checkpoint inhibitor. If the results are encouraging, the goal is to pursue later-stage clinical trial testing through the PanCan Precision Promise adaptive clinical trial platform.
https://pancan.org/news/pancans-5-million-therapeutic-accelerator-award-goes-to-oncolytics-biotech-inc/